Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
about
Recent advances of novel targeted therapy in non-small cell lung cancerRole of HER2 in NSCLCTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughPromising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCRadiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma.Lung cancer immunotherapy.Recent advances in personalized lung cancer medicineA phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerNew targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to knowTargeted therapy in NSCLC driven by HER2 insertionsHER2 in solid tumors: more than 10 years under the microscope; where are we now?The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.A critical appraisal of prognostic and predictive factors for common lung cancers.Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.New targetable oncogenes in non-small-cell lung cancer.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?The ERBB3 receptor in cancer and cancer gene therapySomatic pharmacogenomics in cancer.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerThe impact of genomic changes on treatment of lung cancer.The promise of anti-ErbB3 monoclonals as new cancer therapeuticsRare mutations in non-small-cell lung cancer.New targets in non-small cell lung cancer.Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Assays for predicting and monitoring responses to lung cancer immunotherapy.Emerging targeted therapies in non-small cell lung cancer.Immune Therapy.Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.Today's patients.Understanding and targeting resistance mechanisms in NSCLC.[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
P2860
Q21092930-D3FDCEDD-83FF-4613-A8E2-30CD27516350Q26781683-C20A6DBF-CEC4-49F5-A474-AED553AC6B2FQ26799467-A5C2F57A-3411-40F7-BD14-80FF94704013Q27025970-7C663DAC-E9BB-4958-A342-A1EFA9265EE6Q33427353-FBF1BB01-5644-4996-AFC9-B57D481472B6Q34038203-AE32BFAA-3937-4A16-934F-D54328181B7BQ34146503-CA9D4673-4DA0-4E6E-BB2F-EC77AB3877F5Q34678073-DF98F563-F955-4353-9D3D-CAAB5CE3857DQ34978404-CF30135F-1ECD-4AAB-93A1-C622F59819C3Q35093270-654619DD-D23D-4C90-82B3-36A8E99EC89EQ35200528-9B849026-C819-4D80-BC2B-1A22A9B350B4Q35211263-F1FE9667-C031-4355-A6C0-800233167633Q36266449-51AE37EC-3737-44DE-9B57-FDB6FFFF16FFQ36482542-B3006A3F-B52E-48FF-9C85-D55090491A03Q36488342-95CFB2E8-FDCA-461C-8EBC-FB023EDD0E2EQ36495936-B4FDD649-0106-4E7B-9DFD-2A8689433445Q36660677-C8310FAB-16EA-44AC-9AF8-8DF01B5E0545Q36999705-76AAE361-A6AD-4FA3-B595-7B187B4FDA60Q37135372-A2A84896-4B3A-4E68-B05E-375E7C671865Q37235024-4667DB40-3D78-41BE-8BB1-747DF1CDE63BQ37246286-7B6DBE4E-DF37-45EC-AD11-D8E9BAF00F87Q37304354-C5AEFB12-21FC-4292-9192-720D9CEA15ACQ38034347-252B0BB9-B5F3-4967-8659-9EA380CFAB59Q38104414-11FB0AAB-7E4C-4693-BCE9-B25CBEA22F06Q38114835-43317C6B-3308-4BA4-A33C-8254A662F739Q38267142-79D17E15-2B34-4906-A3EF-FDBCA67E038EQ38390104-6955A9EA-F99A-4BEB-9942-9265468B6DEDQ38514601-56BC97DB-BF99-4BE0-8312-F3CB7938D906Q38547391-3C3C691D-7F2A-4F09-82D0-5B314E1E015BQ38653045-E5C9F105-2264-44CF-B9FF-663D3FDFB8CEQ38669273-DA95739D-AC32-4741-8E6F-F1BD7090258DQ43635123-07B4049D-7AF5-49E4-92A0-5777F167B342Q44615147-D65232EB-766B-4EA6-A654-2C50C8886925Q46915997-0153A97C-C4D8-4E00-9EEB-C89A30A6288BQ53565079-2598430E-520A-4BCB-9C30-BC076FBBB997Q53702598-AB7224C2-7E63-48CB-893C-79A5C53BB7D9
P2860
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@en
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@nl
type
label
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@en
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@nl
prefLabel
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@en
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@nl
P2093
P921
P356
P1433
P1476
Lack of trastuzumab activity i ...... f Cancer and Leukemia Group B.
@en
P2093
Dorothy Watson
Gerald Clamon
James Herndon
Jeffrey Kern
Jennifer Garst
Mark Green
Ramaswamy Govindan
P304
P356
10.1002/CNCR.20950
P407
P577
2005-04-01T00:00:00Z